The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of ruxolitinib in patients with pStat3+ breast cancer.
Nancy U. Lin
Research Funding - Incyte
Rebecca Sue Gelman
No relevant relationships to disclose
Jane E. Brock
No relevant relationships to disclose
Aditya Bardia
No relevant relationships to disclose
Erica L. Mayer
No relevant relationships to disclose
Beth Overmoyer
No relevant relationships to disclose
Vivian Wang
No relevant relationships to disclose
Marie Iannone
No relevant relationships to disclose
Ian E. Krop
No relevant relationships to disclose
Kornelia Polyak
Research Funding - Novartis
Eric P. Winer
No relevant relationships to disclose